#Netherlands #Breast Cancer #ScreenPoint Medical #Biomediq A/S #Nijmegen

ScreenPoint Medical Expands Cancer Risk Assessment Capabilities

ScreenPoint Medical, a leader in breast cancer diagnostic technology, recently announced its acquisition of Biomediq A/S, a research-focused company specializing in quantitative imaging biomarkers. This strategic move aims to enhance the capabilities of ScreenPoint's flagship product, Transpara, which utilizes AI to assist radiologists in identifying breast cancer at earlier stages.

The collaboration between ScreenPoint and Biomediq has been underpinned by ten years of close partnership, and this acquisition marks a significant evolution in their relationship. The integration of Biomediq's technology into Transpara is expected to significantly enhance risk assessment for breast cancer through advanced image analysis. Biomediq's automated analysis system evaluates both 2D and 3D mammograms to predict future breast cancer risks by assessing the heterogeneity of breast tissue, also termed mammographic texture.

A notable publication in 2023 highlighted the potential of combining Transpara’s lesion detection capabilities with Biomediq's quantitative texture analysis. The study titled "Breast Cancer Risk Assessment Using AI for Lesion Detection and Mammographic Texture" demonstrated that when these technologies are combined, they provide a better prediction of breast cancer risk. This innovative approach could potentially double early cancer detection rates for high-risk women during regular screenings, compared to traditional methods.

Transpara stands out as one of the most clinically validated AI-assisted solutions for breast cancer detection available today. It provides radiologists with a reliable second opinion to increase the likelihood of early cancer detection and minimize unnecessary follow-ups. Recently, ScreenPoint introduced Transpara 2.1, the latest algorithm update. This version includes enhancements based on extensive user feedback and clinical data from around the world, and it supports options for automated breast density evaluation and temporal analysis across multiple studies.

Professor Nico Karssemeijer, co-founder and Chief Scientific Officer of ScreenPoint Medical, emphasized the importance of stratified risk detection to optimize patient screening and resource allocation. He stated, “Incorporating Biomediq's risk analysis technology into Transpara will revolutionize breast cancer risk assessment, making it more standardized and accurate for women.”

Echoing this sentiment, Professor Mads Nielsen, co-founder of Biomediq, expressed enthusiasm about the future of their collaboration: “Our long-term partnership with ScreenPoint is rooted in a mutual goal of enhancing detection capabilities for women. This merger will further align our technological advancements with radiological workflows to improve patient care.” Nielsen will continue to support the broader ScreenPoint team as an advisor.

With over 35 peer-reviewed publications backing its efficacy, Transpara has undergone extensive testing across diverse screening populations, proving its capability for identifying interval cancers, which often go unnoticed during traditional assessments. Current findings suggest that nearly 45% of these cancers could be detected earlier with Transpara, significantly alleviating radiological workloads and optimizing workflow solutions.

About Biomediq

Biomediq is dedicated to researching and developing quantitative imaging biomarkers to enhance cancer detection, diagnosis, prognosis, and monitoring processes.

About ScreenPoint Medical

ScreenPoint Medical bridges cutting-edge machine learning research with practical solutions for radiologists, streamlining breast cancer detection workflows, enhancing decision-making confidence, and improving risk assessment processes. Radiologists globally trust Transpara due to its rigorous foundation based on machine learning and image analysis expertise, along with continual updates from global mammography user feedback. For more information, visit ScreenPoint Medical.